Table 1. HRSV positivity rates among SARI cases: annual trends and age-stratified case profiles (2016–2023).
| Year | SARI case | HRSV-positive case (%) | Age-specific distribution | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0–12 months | 13 months−2 years | 2–5 years | 6–11 years | 12–18 years | ||||||||
| n | Pos n (%) | n | Pos n (%) | n | Pos n (%) | n | Pos n (%) | n | Pos n (%) | |||
| 2016 | 245 | 39 (15.9) | 47 | 15 (31.9) | 54 | 10 (18.5) | 99 | 11 (11.1) | 43 | 2 (4.6) | 2 | 1 (50) |
| 2017 | 212 | 23 (10.9) | 35 | 6 (17.1) | 44 | 6 (13.6) | 101 | 11 (10.8) | 31 | 0 (0) | 1 | 0 (0) |
| 2018 | 348 | 40 (11.5) | 55 | 5 (9.1) | 62 | 10 (16.1) | 150 | 20 (13.3) | 76 | 5 (6.6) | 5 | 0 (0) |
| 2019 | 259 | 23 (8.9) | 21 | 6 (28.6) | 45 | 7 (15.6) | 116 | 9 (7.8) | 73 | 1 (1.4) | 4 | 0 (0) |
| 2020 | 123 | 22 (17.9) | 22 | 5 (22.7) | 25 | 7 (28) | 56 | 8 (14.3) | 19 | 0 (0) | 1 | 0 (0) |
| 2021 | 184 | 54 (29.3)* | 27 | 8 (29.6) | 40 | 18 (45) | 98 | 27 (27.6) * | 16 | 0 (0) | 3 | 1 (33.3) |
| 2022 | 303 | 37 (12.2) | 17 | 2 (11.8) | 26 | 2 (7.7) | 151 | 29 (19.2) | 105 | 4 (3.8) | 4 | 0 (0) |
| 2023 | 603 | 40 (6.6)* | 18 | 3 (16.7) | 43 | 8 (18.6) | 213 | 22 (10.3) | 309 | 6 (1.9) | 20 | 1 (5) |
| Total | 2,277 | 278 (12.2) | 242 | 50 (20.7) | 339 | 68 (20.1) | 984 | 137 (13.9) | 672 | 18 (2.7) | 40 | 3 (7.5) |
Age group classified by NICHD paediatric age groups and year.
*Statistically significant differences, as determined by chi-square test P-values adjusted for multiple comparisons using the false discovery rate (FDR) method. The null hypothesis states no significant difference in HRSV positivity rates between the specified group and other groups.